Effects of Interleukin-6 Inhibition on Vascular, Endothelial and Left Ventricular Function in Rheumatoid Arthritis

Sponsor
University of Athens
Study ID
NCT03288584
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • Tocilizumab (Actemra®) — DRUG
    Inhibition of Interleukin-6 activity by tocilizumab (Actemra®) 150mg od, sc injection
  • Other biological agent — DRUG
    Other biological agent (TNFa inhibitor, abatacept, rituximab, IL-1Ra)
  • Corticosteroid and non-biological agents. — DRUG
    Enhanced treatment with corticosteroid and non-biological agents.

Study Details

Recent studies show beneficial effect of the inhibition of interleukin-6 (IL-6) activity on vascular and left ventricular (LV) function. The purpose of this study is to investigate whether anakinra, an IL-6 receptor antagonist, improves vascular, endothelial and LV function in patients with rheumatoid arthritis (RA).

Key Dates

Start date
Oct 27, 2017
Status verified
Apr 2020
Primary completion
Dec 31, 2020
Completion
Dec 31, 2020

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: Tocilizumab
    Inhibition of Interleukin-6 activity by tocilizumab (Actemra®) 150mg od, sc injection
  • Arm: Other biological agent
    Other biological agent (TNFa inhibitor, abatacept, rituximab, IL-1Ra)
  • Arm: Corticosteroid and non-biological agents.
    Enhanced treatment with corticosteroid and non-biological agents.

Primary Outcome Measure

Reduction of pulse wave velocity after treatment with tocilizumab [ Time Frame: 3 months after treatment ]

Central Contacts

Related Studies